Biotech, obesity, Drugs
Obesity Drug From Orexigen Helps Patients Lose Weight in Pivotal Study, Shares Fall Anyway
Luke Timmerman 1/8/09
Updated: Jan. 8, 2:40 pm Pacific–see below: San Diego-based Orexigen Therapeutics said today that a final-stage clinical trial of its experimental obesity drug reached its main goal of helping patients lose weight. The problem is that meeting the goal may not be good enough.
The study, the first of four trials examining the effects of a long-lasting combination of naltrexone and bupropion, showed that patients lost an average of 20.3 pounds... Read more »
Share
